{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:48:40Z","timestamp":1762098520838,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jjcc.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T01:48:13Z","timestamp":1466905693000},"page":"536-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)"],"prefix":"10.1016","volume":"69","author":[{"given":"Erisa","family":"Kawada-Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Arashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2016.05.002_bib0175","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0180","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0185","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0190","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0195","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0200","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5551\/jat.14.45","article-title":"Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese","volume":"14","author":"Teramoto","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan \u2013 2012 version","volume":"20","author":"Teramoto","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0220","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0225","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0230","doi-asserted-by":"crossref","first-page":"e001800","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0235","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0240","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/VHRM.S5551","article-title":"Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals","volume":"5","author":"Saito","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","article-title":"Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion","volume":"34","author":"Zheng","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"Hiro","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0255","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1016\/S1520-765X(01)90108-7","article-title":"Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management","volume":"3","author":"Leitersdorf","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0260","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0265","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0270","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0275","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jjcc.2014.02.026","article-title":"Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: the ZIPANGU study","volume":"64","author":"Hiro","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jjcc.2013.12.008","article-title":"Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study) \u2013 rationale and design","volume":"64","author":"Watanabe","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0285","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0290","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0295","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000116766.31036.03","article-title":"Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia","volume":"109","author":"Salen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0300","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0310","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ahj.2004.10.001","article-title":"A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI registry","volume":"150","author":"Kasanuki","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0315","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehp101","volume":"30","author":"Kasanuki","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0320","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.amjcard.2007.01.024","article-title":"Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology statin evaluation program)","volume":"99","author":"Nagashima","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10557-008-6089-8","article-title":"Long-term nitrate use in acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology nitrate evaluation program)","volume":"22","author":"Yamauchi","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0335","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2005.11.031","article-title":"Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese","volume":"97","author":"Sakamoto","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2016.05.002_bib0340","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716300831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716300831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:56:15Z","timestamp":1760273775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508716300831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0914508716300831"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.05.002","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}